4.8 Article

PD-1 Imposes Qualitative Control of Cellular Transcriptomes in Response to T Cell Activation

Journal

MOLECULAR CELL
Volume 77, Issue 5, Pages 937-+

Publisher

CELL PRESS
DOI: 10.1016/j.molcel.2019.12.012

Keywords

-

Funding

  1. Core Research for Evolutional Science and Technology Program of the Japan Science and Technology Agency
  2. Basic Science and Platform Technology Program for Innovative Biological Medicine of the Japan Agency for Medical Research and Development [JP18am0301007]
  3. Japan Society for the Promotion of Science [JP18H05417, JP19H01029, JP16J08600, JP19K16522]

Ask authors/readers for more resources

Targeted blockade of programmed cell death 1 (PD-1), an immune-checkpoint receptor that inhibits T cell activation, provides clinical benefits in various cancers. However, how PD-1 modulates gene expression in T cells remains enigmatic. Here we investigated how PD-1 affects transcriptome changes induced by T cell receptor (TCR) activation. Intriguingly, we identified a huge variance in PD-1 sensitivity among TCR-inducible genes. When we quantified the half maximal effective concentration (EC50) as the relationship between change in gene expression and TCR signal strength, we found that genes associated with survival and proliferation were efficiently expressed upon TCR activation and resistant to PD-1-mediated inhibition. Conversely, genes encoding cytokines and effector molecules were expressed less efficiently and sensitive to PD-1-mediated inhibition. We further demonstrated that transcription factor binding motifs and CpG frequency in the promoter region affect EC50 and thus the PD-1 sensitivity of genes. Our findings explain how PD-1, dependent on the TCR signal strength, calibrates cellular transcriptomes to shape functional properties of T cell populations.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Multidisciplinary Sciences

PD-1 preferentially inhibits the activation of low-affinity T cells

Kenji Shimizu, Daisuke Sugiura, Il-mi Okazaki, Takumi Maruhashi, Tatsuya Takemoto, Taku Okazaki

Summary: PD-1 preferentially inhibits the expression of TCR-inducible genes when TCR:pMHC affinity is low, demonstrating a qualitative control of T cell responses by suppressing low-affinity T cells. Peptide-MHC affinities and MHC expression levels do not affect PD-1 sensitivity, suggesting that the strength of individual TCR signal is the key determinant of PD-1 sensitivity.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Article Veterinary Sciences

The C-type lectin receptor Clec1A plays an important role in the development of experimental autoimmune encephalomyelitis by enhancing antigen presenting ability of dendritic cells and inducing inflammatory cytokine IL-17

Yulia Makusheva, Soo-Hyun Chung, Aoi Akitsu, Natsumi Maeda, Takumi Maruhashi, Xiao-Qi Ye, Tomonori Kaifu, Shinobu Saijo, Haiyang Sun, Wei Han, Ce Tang, Yoichiro Iwakura

Summary: Clec1A, a member of the C-type lectin receptor family, plays an important role in host defense against Aspergillus fumigatus by recognizing melanin on the fungal surface. This study found that Clec1a(-/-) mice developed milder symptoms in an animal model for multiple sclerosis, suggesting a novel function of Clec1A in the immune system. The reduced production of inflammatory cytokines may be responsible for the amelioration of the disease in Clec1a(-/-) mice.

EXPERIMENTAL ANIMALS (2022)

Article Immunology

DCIR and its ligand asialo-biantennary N-glycan regulate DC function and osteoclastogenesis

Tomonori Kaifu, Rikio Yabe, Takumi Maruhashi, Soo-Hyun Chung, Hiroaki Tateno, Noriyuki Fujikado, Jun Hirabayashi, Yoichiro Iwakura

Summary: The inhibitory C-type lectin receptor DCIR interacts with asialo-biantennary N-glycans to negatively regulate osteoclastogenesis and antigen presentation by dendritic cells, which has important implications for autoimmune and bone metabolic diseases.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Article Immunology

PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity

Daisuke Sugiura, Il-mi Okazaki, Takeo K. Maeda, Takumi Maruhashi, Kenji Shimizu, Rieko Arakaki, Tatsuya Takemoto, Naozumi Ishimaru, Taku Okazaki

Summary: The study presents a method to enhance PD-1 function by targeting the PD-L1-CD80 duplex and demonstrates its effectiveness in alleviating symptoms of autoimmune diseases.

NATURE IMMUNOLOGY (2022)

Article Immunology

Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity

Takumi Maruhashi, Daisuke Sugiura, Il-Mi Okazaki, Kenji Shimizu, Takeo K. Maeda, Jun Ikubo, Harunori Yoshikawa, Katsumi Maenaka, Naozumi Ishimaru, Hidetaka Kosako, Tatsuya Takemoto, Taku Okazaki

Summary: The study identified stable pMHCII as a functional ligand of LAG-3 in both autoimmune and anti-cancer immunity, playing a crucial role in the suppressive activity of LAG-3.

IMMUNITY (2022)

Review Immunology

T-cell-intrinsic and -extrinsic regulation of PD-1 function

Daisuke Sugiura, Kenji Shimizu, Takumi Maruhashi, Il-mi Okazaki, Taku Okazaki

Summary: PD-1 functions are strictly restricted during T-cell activation by the cis-interactions of PD-L1 and CD80, crucial for optimal T-cell responses. Sensitivity to PD-1 effects in T cells is essentially determined by intrinsic factors.

INTERNATIONAL IMMUNOLOGY (2021)

No Data Available